JIC
ALXN

Johnson Investment Counsel’s Alexion Pharmaceuticals ALXN Stock Holding History

Johnson Investment Counsel’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,099
Closed -$569K – 672
2021
Q2 		$569K Sell
3,099
-48
-2% -$8.24K 0.01% 415
2021
Q1 		$481K Sell
3,147
-140
-4% -$21.7K 0.01% 431
2020
Q4 		$514K Buy
3,287
+6
+0.2% +$771 0.01% 399
2020
Q3 		$375K Buy
3,281
+298
+10% +$32.1K 0.01% 429
2020
Q2 		$335K Buy
+2,983
New +$317K 0.01% 456

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Johnson Investment Counsel's ALXN Position: Q3 2021 in Review

Johnson Investment Counsel sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,099 shares — an estimated $569K sold.

Johnson Investment Counsel first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $569K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Johnson Investment Counsel reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Johnson Investment Counsel sold 3,099 Alexion Pharmaceuticals shares in Q3 2021, an estimated $569K.
  • Johnson Investment Counsel first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Johnson Investment Counsel's Alexion Pharmaceuticals position peaked at $569K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Johnson Investment Counsel's 13F filing for Q3 2021, filed 12 Nov 2021.